Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
The Cleveland Clinic
Study ID
NCT06857240
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Dermatomyositis

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.

Key Dates

Start date
Jun 1, 2025
Status verified
Jul 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    1.5 % Ruxolitinib cream

Primary Outcome Measure

CDASI [ Time Frame: 8 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cleveland ClinicClevelandOhio44195
Anthony Fernandez, MD

Find similar trials in Cleveland, OH

By research site
Cleveland Clinic· Cleveland, OH

Related Studies